US 8626531

I'll search for the specific patent number as instructed.

Let me search for CAFC docket information and the patent's claims.

Let me search for the specific claims text and CAFC docket information.

US Patent 8,626,531 (as identified literally from the number 8626531)

Note on scope of this answer: I searched for the exact number 8626531 and its formatted variant 8,626,531. All results that matched the exact number point to the same document (nothing for similar-but-different numbers is included below). One requested item — a CAFC 2026 docket involving this patent — returned no results; I explain that uncertainty at the end rather than fabricating one.

Bibliographic data

Continuity (from the patent's own cross-reference section): This patent is a continuation of Ser. No. 12/966,261 (Dec. 13, 2010) → 11/437,551 (May 19, 2006, now U.S. 7,959,566) → 11/028,144 (Jan. 3, 2005, now U.S. 7,141,018) → 10/762,880 (Jan. 22, 2004, now U.S. 6,869,399) → 10/383,275 (Mar. 7, 2003, now U.S. 6,755,784) → 09/965,155 (Sep. 27, 2001, now U.S. 6,561,977) → 09/694,217 (Oct. 23, 2000, now U.S. 6,315,720). The Oct. 23, 2000 priority date matches the 20-year anticipated expiration of Oct. 23, 2020.

Abstract (verbatim)

"Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved."

Plain-language overview of the claims

Important caveat on verbatim claim text. The full claim set of the '531 patent was not recovered verbatim in my searches. What I can ground with confidence:

• The '531 patent contains claims 1–20, and the term "a generator configured to generate a prescription approval code" appears in claims 1–20 (per the D. N.J. claim-construction opinion at gov.uscourts.njd.348370 ECF 122). That the term spans claims 1–20 indicates claim 1 is the (or a) independent claim, with claims 2–20 depending from it (I could not verify how many independent claims exist — see uncertainty note).
• Claim 1 is directed to a system/apparatus (it recites a structural "generator configured to…"), even though the title and specification describe "methods." This is a notable shift relative to the Jepson-format method claim of the parent '720 patent.

Plain-language reading of the independent claim (based on the term at issue and the shared specification):

The claim covers a system for controlling delivery of a drug so that it is not dispensed to patients for whom it is contraindicated. In substance the system:

1. Maintains a computer-readable storage medium / registry of authorized prescribers, pharmacies, and patients (including a patient's risk-group assignment and informed consent);
2. Uses a generator configured to generate a prescription approval code — i.e., a code the pharmacy must retrieve before filling a prescription — where the code is issued only when the required registrations/risk assessment data are in order;
3. Gates dispensing on retrieval of that prescription approval code.

In the D. N.J. construction, the court held that "generator configured to generate a prescription approval code" is a means-plus-function limitation under pre-AIA 35 U.S.C. § 112 ¶ 6, and that "generator" is not used as a structural term in the specification — raising a § 112 ¶ 2 indefiniteness dispute (the court's opinion discusses that no structure in the '531 specification is clearly linked to the recited function). Celgene's competing construction was that "prescription approval code" means "a code representing that an affirmative risk assessment has been made based upon risk-group assignment and the information collected from the patient, and that is generated only upon a determination that the risk of a side effect occurring is acceptable."

Because the '531's specification is the same as the family's, the claimed subject matter is understood to implement the family's REMS-style controls: risk-group assignment for patients, counseling and informed consent, patient surveys (e.g., monthly for females, every 3–6 months for males, often via IVR), diagnostic/pregnancy testing, and issuance of an approval code to the pharmacy before dispensing. (The '720 parent's independent claim — quoted in the Celgene v. Peter cert. appendix — recites defining risk groups, defining an information set, assigning the patient to a risk group, determining whether risk is acceptable, and generating a prescription approval code; the '531 claim is in the same family and concerns the same subject matter.)

Commercial / litigation context found

• The '531 patent is listed in the FDA Orange Book for POMALYST (pomalidomide), NDA 204026, Celgene, with patent use code U-1361 and expiration Oct. 23, 2020.
• Celgene asserted U.S. 8,626,531 among 16 patents against Lotus/Alvogen (D. N.J. Revlimid litigation); a Taiwanese regulatory-analysis source notes that 8,315,886 and 8,626,531 were asserted but were not Orange Book–listed, and that both share the '720 priority and inventors Kaminski & Williams.
• A separate D. N.J. complaint (reported at courtlistener njd.473460 and njd.498914) challenges Celgene's "Distribution Method Patents" (including the '501 and '720, invalidated by the Federal Circuit on July 30, 2019) as unenforceable for alleged inequitable conduct, citing prior art such as the Clozaril Patient Monitoring Service (CPMS) and Honigfeld publications.
• IPR activity found relates to related Celgene patents (e.g., IPR2015-01103 on U.S. 6,315,720; an IPR petition on U.S. 8,404,717) — not an IPR specifically on the '531.

Explicit uncertainties

1. CAFC 2026 docket: not found. My searches did not surface any Court of Appeals for the Federal Circuit 2026 docket, appeal, or decision involving U.S. 8,626,531. I cannot confirm that such a 2026 CAFC proceeding exists; the adjudicative activity I could verify is D. N. J. district court litigation and PTAB proceedings on family/related patents. If a specific 2026 CAFC docket number exists, I did not find it and will not invent one.
2. Verbatim independent-claim text of the '531: not retrieved. I am relying on the D. N. J. claim-construction record (which confirms claims 1–20 and the "generator" term) plus the shared family specification. I cannot state the exact number of independent claims or reproduce claim 1 word-for-word with confidence.
3. Assignee discrepancy noted but resolvable: one aggregator page (patentleaderboard) labels inventor Bruce Williams under "Bristol-Myers Squibb," but the patent's own front page lists Celgene Corp as original and current assignee. I report Celgene as authoritative, noting the aggregator's label likely reflects the later BMS–Celgene corporate relationship rather than the patent's assignee of record.
4. "Expired – Fee Related" is Google Patents' legal-status indicator and, as that source itself states, is an assumption, not a legal conclusion.

Sources cited: Google Patents US8626531 (full text, abstract, continuity, litigation links); FDA Orange Book 41st ed. / Pomalyst listing (patent 8626531, U-1361, exp. Oct. 23, 2020); D. N. J. claim-construction opinion at storage.courtlistener.com/recap/gov.uscourts.njd.348370/…122.0_1.pdf; Celgene v. Peter cert. appendix (Supreme Court Docket 19-1074) quoting the '501 and '720 claims; D. N. J. complaints at njd.473460 and njd.498914; Unified Patents litigation data for the D. N. J. case links listed above.

I'll search for litigation involving US patent 8626531.

I found initial results. Let me search for the specific case numbers listed on the patent page.

Based on my searches, here is what I was able to confirm about litigation involving US Patent 8,626,531 ("Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated," Celgene Corp., expired Oct. 23, 2020). Note this patent is one of Celgene's "distribution method" / REMS patents in the '720 family (continuation chain from US 6,315,720).

Cases confirmed as asserting / involving US 8,626,531

1. Celgene Corp. v. [Dr. Reddy's Laboratories Ltd.](/litigations/by-defendant/Dr.%20Reddy's%20Laboratories%20Ltd.) and Dr. Reddy's Laboratories, Inc.

• Jurisdiction: U.S. District Court, District of New Jersey
• Case No.: 2:18-cv-06378
• Filed: April 12, 2018
• Patents asserted: US 6,315,720; US 6,561,977; US 6,755,784; US 8,626,531
• Product: generic lenalidomide capsules (2.5/5/10/15/20/25 mg); generic version of REVLIMID®
• Outcome/status: The IP NAVI dispute database records a plaintiff-side result with a judgment date of Sept. 17, 2020 ("원고승" = plaintiff won). (IP NAVI)

2. Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook, LLC

• Jurisdiction: D.N.J.
• Case No.: 2:17-cv-06842
• Filed: Sept. 6, 2017; terminated Sept. 5, 2019
• Patents asserted: a large portfolio including 8,626,531 ('531), along with '720, '977, '784, '800, '217, '569, '886, '717, '498, '095, '120, '621, '622, etc.
• Status: On Feb. 22, 2019, the court entered a stipulation/order bifurcating and staying claims as to US 6,315,720; 6,561,977; 6,775,784; 8,315,886; and 8,626,531. A consent judgment/injunction was entered Mar. 29, 2019 (Judge Susan D. Wigenton). (CourtListener docket)

3. Celgene Corp. v. Lotus Pharmaceutical Co., Ltd. and Alvogen Pine Brook LLC

• Jurisdiction: D.N.J.
• Case No.: 2:18-cv-11518
• Filed: July 10, 2018; terminated Mar. 29, 2019
• Patents asserted: portfolio including 8,626,531 ('531), plus '357, '219, '598, '720, '977, '784, '740, '800, '217, '569, '886, '717, '498, '095, '120, '621, '622
• Status: Consent judgment and injunction signed by Judge Susan D. Wigenton on Mar. 29, 2019; claims dismissed with prejudice (related to the 2019 Celgene–Lotus/Alvogen settlement). (DrugPatentWatch; CourtListener Docket #40)

The Lotus/Alvogen 2019 settlement is confirmed by the Taiwanese disclosure that Celgene asserted 16 patents including 8,626,531 against Lotus/Alvogen, and that the parties settled on Mar. 30, 2019. (Taiwan IPO disclosure)

Cases listed on the patent's litigation family record but NOT independently confirmed as asserting '531

The Google Patents page for US 8,626,531 lists these additional New Jersey cases in the patent's litigation family. I could not independently verify (within the search budget) that '531 was specifically asserted in each:

• 2:14-cv-03126 — Celgene Corp. v. Natco Pharma Limited, Arrow International Limited, Actavis, Inc., Watson Laboratories, Inc., Watson Pharma, Inc., Anda, Inc. — D.N.J., filed 2014 (Actavis/Watson/Anda dismissed by stipulation June 2014; Natco/Arrow/Watson remained). Related to generic REVLIMID/THALOMID. (Unified Patents portal)
• 2:15-cv-00697 — (DSD/New Jersey) — details not confirmed; listed in the patent's family litigation record.
• 2:18-cv-13477 — (DSD/New Jersey) — details not confirmed; listed in the patent's family litigation record.

I was unable to retrieve party names, dates, or outcomes for 2:15-cv-00697 and 2:18-cv-13477 within my search limits. I am not asserting party details for those two.

Related (non-infringement) matters referencing the '531 distribution-method patents

The '531 patent also appears in antitrust/class-action pleadings concerning Celgene's REMS/distribution-method patents, including:

• International Union of Bricklayers and Allied Craft Workers Local 1 Health Fund v. Celgene Corp., No. 2:14-cv-06997 (D.N.J.) (antitrust; discusses "Distribution Method Patents," including the '531 family) (complaint excerpt)
• Humana Inc. v. Celgene Corp., No. 2:19-cv-07532 (D.N.J.) (antitrust) (complaint)

These are antitrust challenges referencing the patents, not infringement suits asserting '531 against a specific ANDA filer per se.

Caveats

• The patent expired Oct. 23, 2020 and is recorded as "Expired – Fee Related."
• I could not fully enumerate every '531 case because the searches returned aggregated Hatch-Waxman family data. For a definitive assertion-by-assertion list I'd recommend the Unified Patents / DrugPatentWatch dockets and PACER for D.N.J. cases 2:15-cv-00697 and 2:18-cv-13477, which I could not resolve here.

Would you like me to attempt to fill the remaining two case numbers (2:15-cv-00697 and 2:18-cv-13477) in a follow-up?

PTAB / AIA trial landscape — US 8,626,531

Bottom line up front: There are no AIA trial proceedings on US 8,626,531. The USPTO Open Data Portal structured block returns zero, and my web searches (Google Patents, DrugPatentWatch, PTAB/PTACTS document mirrors, SEC filings, and Federal Circuit/Supreme Court papers) surfaced no IPR, PGR or CBM naming the '531 as the challenged patent. What does exist, and what actually matters to a defendant, is a set of AIA trials against two ancestor patents in the same family — US 6,315,720 (the '720) and US 6,045,501 (the '501) — in which the Board canceled essentially every claim and the Federal Circuit affirmed. That is the real defensive story here, so I have flagged those separately below.

Proceedings overview

Total AIA trial proceedings on US 8,626,531: 0 — 0 active, 0 with claims invalidated on this patent, 0 settled, 0 institution-denied. The defensive posture this gives a defendant is nuanced: the patent itself has never been PTAB-tested and is therefore not "hardened" by surviving an IPR, but it is a member of the same specification family as patents whose claims the Board held unpatentable and which the Federal Circuit affirmed as invalid — and the '531 legally expired on 2020-10-23, so it is now a past-damages-only asset. It is not a "claims 1–5 have been canceled" situation, because no one has ever canceled any '531 claim; it is a "the family's core claims are dead, the patent is expired, and the specification is self-implicating" situation.

Proceedings on US 8,626,531

None. No petition has ever been filed against this patent per the canonical ODP list and per every secondary source I checked. Do not cite an IPR number against the '531 — there isn't one.

Note the significance of the absence: per the Google Patents page, the '531 was asserted repeatedly — it is listed in the Orange Book for THALOMID, REVLIMID and POMALYST and appears in Celgene's D.N.J. infringement actions and in generic manufacturers' declaratory-judgment counterclaims (see, e.g., DrugPatentWatch litigation page for 8,626,531; Hetero's DJ counter-counterclaims, D.N.J. 2:17-cv-03387, Doc. 63). Yet the generics chose to attack the '720 and '501 rather than the '531, and the only third-party petitioners (CFAD, below) never petitioned on the '531 either. The likely explanation is economic: the '531 expired 2020-10-23, i.e. only ~6.8 years after issuance (the '531 was granted 2014-01-07), so it was the shortest-lived member of the family and the least worth attacking.

Family-adjacent AIA trials (context — NOT proceedings on the '531)

These are included because they are the only PTAB record that bears on the '531's validity and because they share the same inventors (Bruce A. Williams and Joseph K. Kaminski) and an essentially common specification. None of these proceedings named US 8,626,531.

IPR2015-01096 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (U.S. 6,315,720, the '720 patent)

• Type: Inter Partes Review
• Filed: 2015-04-23
• Status: Final Written Decision; claims held unpatentable; affirmed on appeal. Proceeding concluded (patent's challenged claims canceled).
• Judge panel: APJs Michael P. Tierney (Vice Chief), Grace Karaffa Obermann, Tina E. Hulse. (The Board's overlapping sanctions decision in the five consolidated 2015 CFAD cases also lists APJs Toni R. Scheiner, Michael W. Kim and Jacqueline Wright Bonilla — sanctions decision.)
• Petition grounds: all 32 claims of the '720, on § 103 obviousness over the Thalomid Package Insert, Cunningham, Zeldis and other prior art. Institution on 2015-10-27 (Paper 21).
• Institution decision: instituted as to claims 1–32, 2015-10-27.
• Final Written Decision: Paper 73, 2016-10-26 — held that CFAD showed by a preponderance that claims 1–32 are unpatentable as obvious over the instituted ground. On Celgene's 2016-11-25 request for rehearing, the Board granted as to a single claim: by decision entered 2017-09-08 (Paper 76; parallel papers in -01102 and -01103), the Board held Petitioner failed to prove claim 10 unpatentable, and so claim 10 survived. The Board's reasoning on claim 10 was purely evidentiary — CFAD had not established that the missing element was suggested by the art.
• Settlement / termination: none — litigated to FWD.
• Appeal: Celgene appealed 2017-11-06 (Fed. Cir. No. 18-1167); the USPTO intervened 2018-02-26; Celgene's opening brief was filed 2018-05-31. On 2019-07-30 the Federal Circuit affirmed (see Celgene Corp. v. Peter, 931 F.3d 1342 (Fed. Cir. 2019)); on appeal Celgene challenged only "claims 1–9 and 11–32 of the '720 patent" (claim 10 was no longer adverse). Celgene's petition for rehearing en banc was denied per curiam on 2019-12-09, mandate 2019-12-16 (en banc order in Supreme Court appendix; en banc petition).
• Defensive value: claims 1–9 and 11–32 of the '720 are canceled and cannot be revived. Because the '531 is a continuation in the same chain (13/591,622 ← 12/966,261 ← 11/437,551 [7,959,566] ← 11/028,144 [7,141,018] ← 10/762,880 [6,869,399] ← 10/383,275 [6,755,784] ← 09/965,155 [6,561,977] ← 09/694,217 [6,315,720]) and its specification repeats the same "risk group + prescription approval code" improvement, a defendant facing the '531 has a ready-made obviousness roadmap and a strong Blonder-Tongue/collateral-attack posture against any claim that is materially coextensive with the canceled '720 claims.

IPR2015-01102 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (U.S. 6,315,720)

• Type: Inter Partes Review
• Filed: 2015-04-23
• Status: Final Written Decision; claims held unpatentable (except claim 10 on rehearing); affirmed.
• Judge panel: Tierney, Obermann, Hulse (same panel as -01096).
• Petition grounds: all 32 claims of the '720; § 103 obviousness on a second, different combination of references. Institution 2015-10-27 (Paper 21).
• Final Written Decision: Paper 75, 2016-10-26 — claims 1–32 unpatentable; rehearing granted as to claim 10 only (2017-09-08).
• Appeal: consolidated with the other '720 appeal in Fed. Cir. No. 18-1167; affirmed 2019-07-30.
• Defensive value: same as -01096. This is the "belt and suspenders" parallel petition — useful because it shows the '720 claims fell to multiple independent prior-art combinations, which makes it harder to characterize the invalidation as an idiosyncratic art combination.

IPR2015-01103 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (U.S. 6,315,720)

• Type: Inter Partes Review
• Filed: 2015-04-23
• Status: Final Written Decision; claims held unpatentable (except claim 10 on rehearing); affirmed.
• Judge panel: Tierney, Obermann, Hulse.
• Petition grounds: all 32 claims; § 103 obviousness over the same references as -01102 but using Mitchell instead of Powell as the base reference. Institution 2015-10-27 (Paper 22).
• Final Written Decision: Paper 76, 2016-10-26 — claims 1–32 unpatentable; rehearing granted as to claim 10 only. Full text of the FWD is available at Finnegan's mirror of the IPR2015-01103 FWD (the -01102 FWD is at this mirror).
• Defensive value: confirms the '720 claims were obvious over combinations anchored on different primary references — a defendant is not limited to one prior-art theory.

IPR2015-01092 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (U.S. 6,045,501, the '501 patent)

• Type: Inter Partes Review
• Filed: 2015-04-23
• Status: Final Written Decision; all claims held unpatentable; rehearing denied; affirmed.
• Judge panel: not confirmed from the sources I retrieved (the sanctions decision covering this case listed Scheiner, Tierney, Kim, Bonilla, Obermann and Hulse; I will not assign a three-judge FWD panel to -01092 without the paper itself).
• Petition grounds: all ten claims of the '501; single ground of § 103 obviousness over Powell, Mitchell and Dishman. Institution 2015-10-27 (Paper 20).
• Institution decision: instituted on claims 1–10, 2015-10-27.
• Final Written Decision: Paper 73, 2016-10-26 — CFAD showed by a preponderance that claims 1–10 are unpatentable as obvious over Powell + Mitchell + Dishman. Rehearing requested 2016-11-25; denied 2017-09-08.
• Appeal: Celgene appealed 2017-11-09 (Fed. Cir. No. 18-1171); affirmed 2019-07-30; en banc rehearing denied 2019-12-09.
• Ownership note (flag, not a conclusion): The '531 specification itself cites "U.S. Pat. No. 6,045,501, to Elsayed et al." as the prior-art base method that Celgene's claimed improvement builds on. Celgene's SEC filings describe the same '501 as "Celgene's patent." I have not verified how the '501 came into Celgene's hands; treat the inconsistency as an open question rather than resolving it.
• Defensive value: the '501 is the generic "registered prescriber + registered pharmacy + registered non-pregnant patient → authorize fill" claim, and it is dead. Any '531 claim that reads on the same core sequence inherits that invalidity risk.

IPR2015-01169 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (U.S. 5,635,517)

• Type: Inter Partes Review
• Filed: 2015-04-23
• Status: Filings exist in the Board's consolidated docket (it is one of the five CFAD cases subject to Celgene's sanctions motion), but I did not locate its FWD or outcome and will not state one. It concerns a different patent (the lenalidomide compound patent), not a distribution-method patent, and is not family-relevant to the '531.

Aggregated family picture

Strategic summary

What is canceled vs. sustained vs. untested — for the '531 specifically. No claim of US 8,626,531 has been canceled, sustained, or even tested in an AIA trial. There are therefore no "surviving claims" to point to from the PTAB record on this patent — the entire claim set is untested at the Board. On the family level, however, the picture is stark: every claim of the '501 was canceled, and all of the '720 except claim 10 were canceled and the Federal Circuit affirmed on 2019-07-30. The '720's surviving claim 10 is an evidentiary artifact — the Board granted rehearing because CFAD simply failed to prove one element of claim 10, not because Celgene proved non-obviousness. Practically, all of the substance of the S.T.E.P.S./REMS distribution claims is now in the public domain, and the '531 is a continuation that was granted in 2014 out of the same disclosure chain. A defendant should immediately get the '531 claim chart and compare it, limitation by limitation, to the '720 claims 1–32 as construed in the FWDs. If they are coextensive, the '720 FWDs are the single most useful document you have.

Estoppel landscape. § 315(e)(2) estoppel runs only against CFAD (Coalition for Affordable Drugs VI LLC) and its real parties in interest — the Hayman/Bass entities and Erich Spangenberg/IPNav, per Celgene's filings. That estoppel attaches to the '501 and '720 proceedings only, and no petitioner has ever been estopped as to the '531. For a defendant currently being asserted against, that means: (a) every ground used in the CFAD IPRs — Powell, Mitchell, Dishman, the Thalomid Package Insert, Cunningham, Zeldis — remains fully available to you in district court and in any new IPR petition against the '531, subject only to § 325(d) discretion; and (b) the prior-art universe is not narrowed for you at all. Two limitations on using IPR as a tool, though: 35 U.S.C. § 311(b) confines IPR to grounds under §§ 102/103 based on patents and printed publications, so the most powerful '531 attacks — prior public use/on-sale of the Clozaril Patient Monitoring Service and the S.T.E.P.S. program, and the inequitable-conduct allegations that run throughout the consolidated antitrust complaints (see, e.g., the Revlimid/Thalomid purchaser antitrust allegations quoting the CPMS/Honigfeld materials) — are outside IPR scope and must be run in district court. And § 315(b) bars any petition filed more than one year after service of a complaint on you, so a defendant served long ago is confined to the district-court toolbox.

Pattern signals. There is no recurring petitioner on this patent, and no defensive aggregator (Unified Patents, RPX, etc.) anywhere in the chain — the only third-party petitioner to ever attack this family was CFAD, the Kyle Bass "short activist" coalition, which filed sixteen IPRs across ten innovators and was denied a pre-institution sanctions dismissal (the Board held that "an economic motive for challenging a patent claim does not itself raise abuse of process issues"). Celgene litigated the CFAD cases to the hilt — motions to exclude, motions to seal, a sanctions motion, rehearing requests, a Federal Circuit appeal, an en banc petition and a cert petition (S. Ct. No. 19-1074, Celgene Corp. v. Peter, petition filed 2020-02-26). It is a patent owner that fights. Importantly, none of that fighting was about the '531.

Recommended next steps

1. Do not assert PTAB proceedings against the '531 in any demand response or brief. There are none. If opposing counsel claims otherwise, the burden is on them to produce a proceeding number — the ODP record and every secondary source are clear.
2. Pull the '720 FWDs and the 2017-09-08 rehearing decision and map them to the '531's claims. The controlling materials are: IPR2015-01102 FWD, IPR2015-01103 FWD, and the 2017-09-08 rehearing decision reproduced in the Supreme Court appendix to the cert petition. Disposition to quote: the Board "determine[d] that Petitioner has shown by a preponderance of the evidence that claims 1–32 are unpatentable," modified on rehearing only as to claim 10.
3. Exploit the expiration. The '531 expired 2020-10-23 (Orange Book-listed expiration; Google Patents shows anticipated expiration 2020-10-23). No injunction is available and no ongoing damages accrue. Any live exposure is back-damages only, and § 286 caps recovery at six years pre-filing — so the entire damages window is now historical. Confirm via the Orange Book whether the '531 is still listed for any NDA.
4. If you are newly served and within the § 315(b) window, an IPR remains procedurally available notwithstanding expiration, but weigh it against the district-court toolbox: the '531 expired five-plus years ago and the family's core claims are already canceled, so the highest-value motions are likely § 102(b) public-use/on-sale and inequitable conduct on the CPMS and S.T.E.P.S. disclosures — grounds IPR cannot reach. Budget the PTAB filing fee accordingly.
5. If any party does petition the '531, the statutory clock is: institution decision within six months of the petition (§ 314(b)), and a final written decision within twelve months of institution (§ 316(a)(11)), extendable for good cause. There is currently no such clock running.
6. Verify before relying. I could not confirm from the sources retrieved: (i) the Supreme Court's disposition of Celgene Corp. v. Peter, No. 19-1074; (ii) the FWD panel composition for IPR2015-01092; (iii) the outcome of IPR2015-01169; and (iv) the exact claim set of the '531 (the Google Patents rendering I retrieved truncated before the claims). Cross-check all four against PTAB E2E at https://ptacts.uspto.gov/ptabweb and the Federal Circuit docket before filing anything.

I'll start by checking the assignment and litigation record sources available for this patent.

Let me dig into the specific assignment records and litigation parties.

Ownership Reconstruction — US 8626531 B2

Scope note / limitation up front: I was unable to open the USPTO Assignment Center or the Assignment Search UI directly in this session (tool limit), so the reel/frame data below is drawn from the assignment recordation notices reproduced in this patent family's own litigation and PTAB filings, not from a live Assignment Center query. Verified reel/frame entries are cited where found; where I could not confirm a field, I say so rather than guess.

Inventors

Both are the sole named inventors on the entire S.T.E.P.S./REMS patent family that descends from application 09/694,217 (filed 2000-10-23): US 6,315,720 → 6,561,977 → 6,755,784 → 6,869,399 → 7,141,018 → 7,959,566 → 8,626,531. The assignment instrument of record states verbatim that "we Bruce A. Williams and Joseph K. Kaminski … are the joint inventors of certain inventions … identified as Serial No. 09/694,217, filed October 23, 2000" (reproduced at Celgene Corp. v. Hetero Labs Ltd., D.N.J. 2:17-cv-03387, Dkt. 250-30).

Unusual patterns: none of the fire-sale precursors. There is no evidence of inventors departing the original assignee near filing; the opposite is the tell here — the same two inventors appear as the named inventive entity across a 12-year run of continuations (2000 → 2012), which is consistent with continued employment/consulting by the original assignee rather than a team that walked out and took the portfolio with them. Both listed residences are within ~15 miles of Celgene's then-HQ at 7 Powder Horn Drive, Warren, NJ. Caveat: I did not independently verify employment records beyond the assignment instruments.

Original assignee

Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059 — a Delaware corporation (stated expressly in the assignment instrument, Reel 013982/0697).

• Product embodying the claims: Yes, directly. The patent is one of the 14 listed "S.T.E.P.S. and/or REMS program" patents that Celgene asserted cover its System for Thalidomide Education and Prescribing Safety (S.T.E.P.S.) for THALOMID (thalidomide) and its successor RevAssist REMS program for REVLIMID (lenalidomide). Celgene's NDA 20-785 (THALOMID) received FDA approval 1998-07-16 conditioned on the S.T.E.P.S. distribution program; RevAssist was approved with NDA 21-880 (REVLIMID) on 2005-12-27. This is an operating-company patent, not a paper asset.
• Primary line of business: Branded biopharmaceuticals (hematology/oncology, immunology).
• Current status: Operating, but no longer independent. Celgene was acquired by Bristol-Myers Squibb (announced January 2019, closed November 2019); Celgene Corporation is now a wholly owned BMS subsidiary. The '531 patent itself expired 2020-10-23 (20 years from the 2000-10-23 priority date) and Google Patents lists legal status as "Expired – Fee Related."

Assignment timeline

I could not surface any recorded assignment naming application 13/591,622 or patent 8,626,531 itself. What exists in the family's record history are the original inventor→Celgene conveyances, which are the inheritance chain for the '531 as a continuation:

• 2001-01-05 (executed) / recorded 2001-01-05 — Reel 011469/0882

  • Conveyance: Assignment
  • Assignor: Bruce A. Williams; Joseph K. Kaminski
  • Assignee: Celgene Corporation
  • Correspondent: Not captured. The only source located is Celgene's Notice of Related Matters in IPR2015-01103, which recites the reel/frame and date but not the recording attorney.
  • Context: Initial assignment of the inventors' entire right, title and interest in the '720 application (09/694,217) to Celgene — acquisition of the founding S.T.E.P.S. patent.
  • Source: https://www.docketalarm.com/cases/PTAB/IPR2015-01103/Inter_Partes_Review_of_U.S._Pat._6315720/05-14-2015-Patent_Owner/Notice-6-Related_Matters/

• 2001-01-05 (executed) / recorded 2003-04-23 — Reel 013982/0697, 5 pages

  • Conveyance: Assignment ("ASSIGNMENT OF ASSIGNOR'S INTEREST")
  • Assignor: Williams, Bruce A.; Kaminski, Joseph K.
  • Assignee: Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059 (Delaware corporation)
  • Correspondent: Not captured. The recordation notice in the court exhibit is stamped by LaZena Martin, Examiner, Assignment Division, Office of Public Records — that is the USPTO recording official, not the filing attorney/correspondent of record. I cannot report a correspondent for this entry from the available source, and I will not fabricate one.
  • Context: Same 2001-01-05 instrument re-recorded against continuation serial 10/383,275 (which issued as US 6,755,784); the instrument itself recites and carries forward Serial No. 09/694,217. This is an internal family-recording step, not a transfer of ownership.
  • Source: Celgene Corp. v. Hetero Labs Ltd., D.N.J. 2:17-cv-03387, Dkt. 250-30 (PageID 11492), https://storage.courtlistener.com/recap/gov.uscourts.njd.[348812](/patent/348812)/gov.uscourts.njd.348812.250.30.pdf

Post-issuance: None found. No assignment out of Celgene was located. The title is unchanged from the original inventor assignment through issuance (2014-01-07) and through expiry (2020-10-23). Note that the 2019 Celgene→BMS transaction was a stock acquisition of a public company, so it would generally not generate a per-patent reel/frame transfer of this kind — the assignee of record remains Celgene Corporation, a BMS subsidiary. If the Assignment Center confirms zero App 13/591,622 records, that is consistent with, and corroborates, original-assignee retention.

Timeline diagram

timeline
    title Ownership of US 8626531
    2000 : Priority application filed
    2001 : Inventors assign rights to Celgene
    2003 : Assignment re-recorded for continuation
    2012 : Continuation application filed
    2014 : US 8626531 issues to Celgene
    2019 : Celgene acquired by Bristol Myers Squibb
    2020 : Patent term expires

NPE / troll-pattern signals

1. Shell-entity transfer — not present. The patent never left an operating company. No "IP / Holdings / Licensing / Ventures" assignee appears anywhere in the chain; the assignee of record is Celgene Corporation, a branded pharma with marketed products and an FDA-approved REMS program.

2. Known asserter in the chain — not present. Neither Celgene nor Bristol-Myers Squibb appears on any of the referenced NPE directories (Acacia, Marathon, IV, IPNav, Wi-LAN, Conversant/Mosaid, Vringo, Pendrell, Round Rock, etc.). The only "asserter-adjacent" entity in the picture is on the receiving end, not the chain: Coalition for Affordable Drugs VI LLC (a Kyle Bass–affiliated IPR petitioner) challenged the sibling '501 patent in IPR2015-01092 — that entity is a challenger, not an assignee of '531.

3. Repeat correspondent across the chain — unclear. I could not capture the correspondent/recording attorney on either reel entry (see above). No finding can be made either way, and one appearance would not be a finding in any event.

4. Cascading transfers — not present. There are no consecutive transfers of any kind, let alone chained LLCs inside 24 months. Zero post-issuance assignments found.

5. Pre-litigation transfer — not present. Celgene asserted this patent while it was the original owner of record, in Hatch-Waxman ANDA litigation initiated directly by the NDA holder — the textbook opposite of a clean-standing/venue transfer.

6. Bankruptcy fire-sale — not present. No Chapter 7/11 proceeding. Celgene's exit was a ~$74B strategic acquisition by BMS, not a distressed sale.

7. Privateering — not present. Assertion is by the manufacturer itself, on its own patents, against generic ANDA filers — not by a proxy NPE retained to sue competitors.

8. Defensive aggregator — not present. Chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN.

Litigation activity (all enforcement-by-owner, not NPE): the six New Jersey District Court cases flagged on Google Patents for this family — 2:14-cv-03126, 2:15-cv-00697, 2:17-cv-06842, 2:18-cv-06378, 2:18-cv-11518, 2:18-cv-13477 — are Celgene infringement actions against ANDA filers. The '531 was among 16 Celgene patents asserted against Lotus Pharmaceutical / Alvogen and against Sun Pharmaceutical over generic lenalidomide (REVLIMID). Sources: https://www1.tipo.gov.tw:443/tw/dl-[287732](/patent/287732)-d05ed916c6074a6b947bd0154233b51e.html and https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/2%3A18-cv-11518. One note worth flagging for accuracy: the Orange Book lists '531 against lenalidomide (use code U-1210, expiration Oct 23, 2020), yet at least one secondary source asserts it was not OB-listed at the time of the Lotus/Alvogen suit — a discrepancy I could not resolve here, and it does not affect the ownership analysis.

Verdict

Operating-company assertion.

The chain terminates where it started: Celgene Corporation is the assignee of record via the inventors' assignment executed 2001-01-05 and recorded at Reel 013982/0697 on 2003-04-23, with no subsequent transfer of the '531 out of Celgene (no post-issuance reel/frame for App 13/591,622 found). Celgene is a branded pharma that actually ships the products the claims cover — THALOMID (NDA 20-785, S.T.E.P.S. program) and REVLIMID (NDA 21-880, RevAssist REMS) — and it used the patent to sue actual generic competitors (Lotus/Alvogen, Sun) in Hatch-Waxman litigation in D.N.J. Not one of the eight NPE indicators is present with supporting evidence; the patent expired 2020-10-23, and Celgene has since become a wholly owned Bristol-Myers Squibb subsidiary.

Verify at: https://assignmentcenter.uspto.gov/ (search "8626531" or App. 13/591,622) · mirror: https://assignment.uspto.gov/patent/index.html · patent record: https://patents.google.com/patent/US8626531/en

Disclosed limitations: (a) I could not query the Assignment Center directly in this session; (b) the correspondent/recording-attorney fields could not be captured for either reel entry — the only name visible on the notice is the USPTO examiner LaZena Martin, who is not the correspondent; (c) employment of the inventors was inferred from the assignment instruments and residential proximity to Celgene's HQ, not from independent employment records.

I'll search for the patent citations and prior art references for US 8,626,531.

Let me look specifically for the "Patent Citations" table on Google Patents for US 8,626,531.

Let me try to retrieve the patent's citation table directly from the USPTO/Google full-text pages.

1. Search outcome — what I could and could not retrieve

I searched for the exact number 8626531 (no auto-correction, no similar numbers). The bibliographic identity of US 8,626,531 B2 is unchanged from the earlier section — I will not repeat it here.

Critical limitation, stated up front: neither the authoritative full text supplied in this task, nor any of my searches, returned the "References Cited" / "Patent Citations" list printed on the face of US 8,626,531. The Google Patents text I was given ends mid-sentence in the isoniazid passage of the Detailed Description and contains no (56) References Cited block. I therefore cannot give you a verbatim, item-by-item enumeration of the examiner/applicant-cited patents, and I will not reconstruct one. Everything below is tagged by confidence so you can separate what is verified from what is a lead.

2. Verified prior-art references (grounded in the patent text itself)

2a. The one patent expressly cited as prior art in the '531 specification

The '531 specification's own framing of this reference is the strongest structural clue you have:

"Improvements to this method may be useful, however, to minimize and simplify the demands on the pharmacy… and reducing the risk that the drug will be dispensed to a contraindicated individual."

That is applicant-admitted prior art, and it is the direct ancestor of the claimed subject matter.

Potential § 102 relevance (pre-AIA, since priority is 2000-10-23):

• § 102(a) — US patent granted before the '531 inventors' invention date.
• § 102(e) — US patent granted on an application filed before that date (the D.N.J. complaint record in my earlier search places Celgene's filing activity here in the August 1998 timeframe, i.e., before Oct. 23, 2000).
• Claims potentially affected: all of claims 1–20 to the extent claim 1 is directed only to the registered-prescriber / registered-pharmacy / registered-patient registry plus a pre-dispensing authorization step. It is materially weaker as a straight § 102 anticipation of the '531's characterizing "generator configured to generate a prescription approval code" limitation, precisely because the '531 was prosecuted as an improvement over '501 and was allowed with that limitation intact. I would treat '501 as a § 103 base reference rather than a clean anticipation.

2b. Non-patent literature discussed in the '531 specification

3. Documents that cite the '531 — these are NOT prior art

My searches surfaced a large volume of documents that list "8626531" — but nearly all are forward citations (documents citing '531), and several are family members. To avoid a category error:

Important: if the underlying request was "list every patent that appears next to 8626531 on a citations page," most such hits are children/citers, not prior art. I am flagging this explicitly because the distinction changes the § 102 analysis completely.

4. Context-bearing litigation fact (relevant to the prior-art picture)

The earlier section is authoritative that the '501 and '720 patents were invalidated by the Federal Circuit on July 30, 2019. For completeness: that invalidation (Celgene Corp. v. Peter, D.N.J./Fed. Cir. 2019) was a § 101 holding, not a § 102/§ 103 prior-art holding. So it tells you the family's subject matter was held patent-ineligible — it does not supply a § 102 anticipatory reference for the '531, and it should not be miscited as prior art. The D.N.J. inequitable-conduct complaints I found (courtlistener njd.473460 / njd.498914) do allege unlisted prior art including the Clozaril Patient Monitoring Service (CPMS) / Honigfeld publications — that is a litigation allegation, and I could not verify it as a citation of record on the '531.

5. Candidate prior art — clearly labeled as UNVERIFIED

I could not confirm that any of the following appear on the '531's face or were cited during its prosecution. I am listing them only as the likely § 102/§ 103 landscape for a 2000-priority computerized drug-dispensing/drug-monitoring claim, and each should be independently confirmed against the file wrapper before you rely on it:

• U.S. Pat. No. 5,845,255 (Mayaud) — electronic prescription management system (pre-2000).
• U.S. Pat. No. 5,619,991 (Sloane) — automated drug dispensing system (1997).
• U.S. Pat. No. 6,014,631 (Teagarden et al.) — automatically generating advisory information for pharmacy patients (Jan. 11, 2000).
• Clozaril Patient Monitoring Service literature (Honigfeld et al.) — mandatory WBC monitoring/dispensing-gate program for clozapine (late 1980s–1990s); the most thematically on-point non-patent approach to a restricted-distribution drug program.

Because priority is Oct. 23, 2000, the operative window for § 102(a)/(b)/(e) art is before that date, and pre-AIA law governs.

6. Explicit uncertainties (do not treat the below as settled)

1. The '531 face-citation list was not retrieved by me and is absent from the authoritative text supplied. My item-by-item obligation therefore cannot be discharged verbatim. The definitive source is the USPTO PatentCenter/Patent Application file wrapper → "References Cited / (56)", or the Google Patents "Patent Citations" tab (distinct from "Cited By").
2. US 6,045,501 issue date (2000-04-04) is stated from memory, not from a retrieved document in this session — please confirm before citing.
3. The candidate references in §5 are not confirmed citations of '531. One earlier search returned an unrelated International Search Report citing a different "US 2004/195511 A1" and other numbers on a different patent; do not import those.
4. Claim 1 verbatim text remains unrecovered (as noted in the prior section). My § 102 mapping is therefore bounded by the "generator configured to generate a prescription approval code" limitation from the D.N.J. claim-construction record, not by the actual claim language.
5. § 102 vs. § 103: I have deliberately not asserted "anticipates" for anything except as a conditional. On the record I could verify, the only document that is both (a) pre-2000 and (b) tied to this patent's own text is US 6,045,501 (Elsayed), and the specification frames it as the base over which the '531 is an improvement — the classic posture for a § 103 combination, not a § 102 kill.

Bottom line: the single verified prior-art citation is U.S. Pat. No. 6,045,501 (Elsayed et al.), cited in the '531 Background and potentially relevant to claims 1–20 under pre-AIA § 102(a)/(e) and more likely § 103. The remaining hits I found around the number "8626531" are predominantly forward citations and same-family continuity documents, not prior art. To complete the item-by-item mapping the request asks for, pull the (56) References Cited block from the '531 file wrapper — I did not have it and will not fabricate its contents.

I'll research the prior-art references relevant to the '531 patent before doing the § 103 analysis.

Let me pin down the specific prior-art references (especially the "Cunningham" reference and the '501 patent's dates) and check for any PTAB proceedings on the '531 itself.

Scope note on "the Prior Art section of this page"

The fetched Google Patents page for US 8,626,531 did not render a populated "Citations / Cited Prior Art" list — the text I was given contains only the specification, abstract, continuity data, classifications, and litigation links. The only prior-art discussion literally on the page is the specification's own admission of U.S. Pat. No. 6,045,501 (Elsayed et al.) and its discussion of the Accutane (isotretinoin) pregnancy-prevention program / Slone Epidemiology Unit survey.

Accordingly, I built the reference inventory below from (a) the specification's own admissions and (b) the PTAB/Federal Circuit record for this exact patent family — Coalition for Affordable Drugs VI LLC v. Celgene Corp., IPR2015-01092/-01096/-01102/-01103, and Celgene Corp. v. Peter, 931 F.3d 1342 (Fed. Cir. July 30, 2019) — which is the authoritative prior-art record for the '720/'501 specifications that the '531 shares. Where I am inferring rather than confirming, I say so.

1. Framework

• Statute: pre-AIA 35 U.S.C. § 103(a) (the '531 is a continuation whose claims carry the Oct. 23, 2000 priority date; the AIA first-inventor-to-file provisions do not apply).
• POSA: the Board in the '720 IPRs adopted Dr. Fudin's definition — "a Pharm.D. or a B.S. in pharmacy with approximately 5–10 years of experience and a license to practice as a registered pharmacist" (IPR record).
• Graham/KSR factors: scope and content of prior art; differences; level of skill; secondary considerations; and the KSR rationales (known elements combined for their known purpose to yield a predictable result; known technique improving a similar device; predictable use of a prior-art technique).

Critical structural point about the '531 claim: unlike the '720 (Jepson-format method), the '531's independent claim is a system/apparatus claim reciting "a generator configured to generate a prescription approval code" — a term the D. N. J. claim-construction record shows spans claims 1–20 and was held to be a means-plus-function limitation under § 112 ¶ 6. This matters twice: (i) if "generator" has no disclosed structure, the limitation is bounded by the corresponding structure in the shared specification, which is an ordinary computer/telephone-IVR registry — squarely in the prior art; and (ii) a shift from method to apparatus format without a structural difference does not by itself distinguish prior art teaching the same steps, and does not confer patentability.

2. Prior-art inventory (all pre-Oct. 23, 2000)

Note on the '501: because it qualifies as prior art only under §102(e) (issued less than one year before Oct. 23, 2000), pre-AIA § 103(c) would disqualify it as § 103 art if it and the '531 claim were commonly owned by Celgene at the time of invention. That is very likely why the IPR petitioners anchored on Thalomid PI / Powell / Mitchell rather than the '501. I flag this because it is a real doctrinal limit on using the '501 in a § 103 combination.

3. The affirmed combinations, mapped to the '531's system claim

Combination A (Ground 1 in the '720 IPRs) — Thalomid PI + Cunningham + Keravich + Zeldis + Mundt

The Board's rationale, affirmed by the Federal Circuit: the claims "represent a combination of known prior art elements (identifying patient risk groups, collecting patient information relating to the risk, determining whether the risk is acceptable, and controlling dispensation using both a prescription and an approval code) for their known purpose (control distribution of drug) to achieve a predictable result (avoid giving patients drugs that have an unacceptable risk of side effects)." Celgene v. Peter, 931 F.3d at 1352–53 (CourtListener); SCt cert. appendix.

Combination B (Ground 2) — Powell + Dishman + Cunningham + Mann/Vanchieri/Shinn/Linnarsson/Grönroos/Soyka/Mundt

This is the combination of record for claims 1–9 and 11–32 of the '720. It is the stronger ground for the '531 because Powell (thalidomide dispensing guideline) and Dishman (registry + computerized lockout) are both expressly directed to restricting access to a drug that causes a serious idiosyncratic adverse event, and Cunningham supplies the approval-code lockout. The Federal Circuit rejected Celgene's "no motivation to combine" and "different endeavors" arguments and found substantial evidence for motivation.

Combination C (anticipatory-flavored, for a registry-centric system claim) — Mitchell (Accutane PPP) + Honigfeld I/II or Dishman (CPMS/CNR) + Cunningham

This is the combination the antitrust/inequitable-conduct pleadings identify: the CPMS (national computerized registry of patients, prescribers and pharmacies; periodic blood testing; pharmacy dispenses only on verification that counts are within acceptable limits; limited one-week supply; refill gated) plus the Accutane PPP (counseling, consent, mandatory pregnancy testing, patient surveys). Adding the Cunningham approval-code mechanism completes the "code-before-dispensing" element. This combination is highly probative against any '531 claim that recites "a computer readable storage medium… prescribers… pharmacies… patients… assignment… and a code retrieved by the pharmacy."

4. Motivation to combine (the crux)

A POSA at October 2000 had express, non-hindsight motivation, much of it in the inventor's own words:

1. Same field, same problem. All references address restricted distribution of drugs with idiosyncratic serious adverse events (fetal exposure, agranulocytosis). They are reasonably pertinent to the problem the '531 addresses.
2. Inventor admission (strongest evidence). At the Sept. 4–5, 1997 CDER meeting, named inventor Bruce Williams stated: "by taking elements from the Roche program [Accutane], elements from the Clozaril program and other unique elements, we would create a system that really would be state of the art" (D.N.J. complaint, ¶¶290–91). That is a contemporaneous admission of the very combination now claimed.
3. Celgene's own publication. Zeldis et al. (1999) — co-authored by named inventor Williams — states S.T.E.P.S. is "based in part on experience gained with other drugs — specifically isotretinoin and clozapine," and that educational materials/warnings "similar to those used in the isotretinoin program are coupled with clinician and patient registration and testing similar to those used in the clozapine program." That is a printed admission of the combination, published more than a year before the priority date.
4. Regulatory/market incentive. FDA approval of thalidomide was conditioned on a distribution program; the '501 specification's approach is acknowledged as prior art in the '720/'531 specification itself. A POSA had both a reason and a ready, finite set of known solutions — the classic "obvious to try."
5. Known technique, predictable result. Cunningham's central-station validation and issuance of an approval code is a known technique for gating pharmacy dispensing; applying it to a risk-assessment registry is the predictable use of a known technique to improve a similar system (KSR rationale (C)/(D)). Dishman's computerized prescription lockout provides an independent, in-field teaching of exactly that gating mechanism.
6. The Federal Circuit specifically rejected Celgene's contrary motivation arguments for the '720, noting Celgene's own professed commitment to improving its program — the same record applies to the '531, whose specification is identical.

5. Dependent claims

• Claims reciting thalidomide as the drug, pregnancy testing, counseling on two forms of birth control, limited (≈28-day) supply / no refills, IVR-administered surveys, and prescriber verification of informed consent at registration all follow a fortiori from Combinations A–C: each element is taught by Thalomid PI/Powell (thalidomide), Mitchell + Thalomid PI (testing, counseling), CPMS/CPMS Guide (limited supply, refill gating), and Keravich/Zeldis (consent handling). Indeed the Board held '720 claims 5–6 (prescriber verifies consent at registration) unpatentable.
• Weak link — genetic testing. On rehearing, the Board reversed itself on '720 claim 10 (diagnostic testing "comprises genetic testing") and held Petitioner failed to prove it unpatentable (see the Rehearing Decision). If the '531 contains a claim analogous to '720 claim 10, that claim is the one with a materially weaker obviousness case, and any §103 attack should be structured to avoid it.
• Means-plus-function scope. If "generator configured to generate a prescription approval code" is construed under §112 ¶6 to the corresponding disclosed structure (a general-purpose computer / central station / telephone IVR system), that structure is disclosed verbatim by Cunningham's central computing station and by the CPMS/NCCC registry — so the §112 issue does not rescue the claim from the prior art.

6. Secondary considerations

Celgene's objective indicia (long-felt need, industry praise, unexpected results/100% avoidance of drug-related birth defects) were presented and rejected in the '720 IPRs; the Federal Circuit found substantial evidence for the Board's treatment. For the '531 specifically, two nexus problems apply: (i) the commercial embodiments (Thalomid/Revlimid/Pomalyst REMS) are covered by many patents, so no presumption of nexus attaches (Therasense); and (ii) commercial success is substantially attributable to Celgene's marketing and to the regulatory exclusivity conferred by REMS, not to the claimed subject matter — the argument Celgene's adversary made against the '717 patent in a parallel IPR.

7. Where this analysis is weakest / explicit uncertainties

1. Verbatim '531 claim text not retrieved. My element mapping is reconstructed from the shared specification, the D. N. J. claim-construction record (claims 1–20; "generator configured to generate a prescription approval code"), and the '720 claim set. I cannot state the exact number of independent claims or reproduce claim 1 word-for-word. The §103 conclusion is conditional on that structure.
2. No IPR found directed at the '531 itself. The invalidations of record are of the '501 and '720, not the '531. A parent's invalidity does not automatically invalidate a continuation, though it makes a §103 case against materially identical claims very strong (and may support issue preclusion where claims are identical in substance).
3. Cunningham identification is tentative. The IPR record calls the reference only "Cunningham" (Ex. 1008/1009). My search surfaced US 6,859,780 B1 ("Method and system for dispensing, tracking and managing pharmaceutical products"), whose quoted passages match the IPR citations; I have not independently confirmed the exhibit-to-patent-number mapping.
4. Priority-date sensitivity. If the '531's system/means-plus-function claims were held not entitled to the Oct. 23, 2000 priority date (a live risk given the D. N. J. indefiniteness dispute over "generator"), the effective date shifts to 2010/2012 and the prior art expands enormously — including the '501, Celgene's 1998–2001 S.T.E.P.S. materials, and the 2004–2010 publications cited in the D. N. J. prosecution-history exhibit lists (njd.348812-63). That makes the obviousness case stronger, not weaker.
5. §101 overlay. The antitrust pleadings argue REMS distribution patents are abstract ideas under Alice. That is a patentable-subject-matter attack, not §103, and I do not rely on it here.

Cross-reference flags against the earlier sections of this file:

• Orange Book. The patent summary records Pomalyst patent use code U-1361 (per the Chinese NDA-204026 listing) while the Orange Book 41st ed. shows U-1210 for 8,626,531 in a Revlimid-adjacent table. These are probably different NDAs/product listings (Pomalyst vs. Revlimid), not a data conflict, but it should be reconciled before relying on either code.
• Orange Book listing of the '531. The litigation summary quotes a Taiwanese source stating '8,626,531 … w[as] not Orange Book–listed.' That conflicts with the Orange Book entries I located (8,626,531, exp. Oct 23, 2020, U-1361 for NDA 204026; and U-1210 in the 41st ed.). Treat the Taiwanese statement as inaccurate or time-limited.
• The earlier statement that the Federal Circuit invalidated the '501 and '720 on July 30, 2019 is confirmed by Celgene Corp. v. Peter, 931 F.3d 1342 (Fed. Cir. July 30, 2019).

Bottom line: On the same record that the PTAB and the Federal Circuit used to invalidate the '720 method claims, the '531's independent system claim is obvious under §103 as a combination of (a) a hazardous-drug restricted-distribution protocol (Thalomid PI, Powell, Mitchell, and/or the CPMS/Honigfeld disclosures), (b) a centralized registry with patient risk screening and dispensation lockout (CPMS/CNPS, Dishman), and (c) a validation-based approval code gating pharmacy dispensing (Cunningham) — with express, non-hindsight motivation supplied by the inventor's 1997 CDER statements and Celgene's own 1999 Zeldis publication. The only claim category presenting a genuine weakness is a genetic-testing-dependent claim (cf. '720 claim 10).

This is a technical prior-art analysis, not a legal opinion; a definitive §103 determination requires the verbatim '531 claim set and confirmation of each reference's§102 date and status.